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Nuclear Phosphoproteomic Screen Uncovers
ACLY as Mediator of IL-2-induced Proliferation
of CD4 T lymphocytes*□S
Nerea Osinalde‡ ‡‡, Jone Mitxelena§ §§, Virginia Sa´nchez-Quiles‡¶¶,
Vyacheslav Akimov‡, Kerman Aloria¶, Jesus M. Arizmendi, Ana M. Zubiaga§,
Blagoy Blagoev‡, and Irina Kratchmarova‡**
Anti-cancer immunotherapies commonly rely on the use
of interleukin-2 (IL-2) to promote the expansion of T
lymphocytes. IL-2- dependent proliferation is the culmi-
nation of a complex network of phosphorylation-driven
signaling events that impact on gene transcription
through mechanisms that are not clearly understood. To
study the role of IL-2 in the regulation of nuclear protein
function we have performed an unbiased mass spec-
trometry-based study of the nuclear phosphoproteome
of resting and IL-2-treated CD4 T lymphocytes. We
detected 8521distinct phosphosites including many that
are not yet reported in curated phosphorylation data-
bases. Although most phosphorylation sites remained
unaffected upon IL-2 treatment, 391 sites corresponding
to 288 gene products showed robust IL-2-dependent
regulation. Importantly, we show that ATP-citrate lyase
(ACLY) is a key phosphoprotein effector of IL-2-medi-
ated T-cell responses. ACLY becomes phosphorylated
on serine 455 in T lymphocytes upon IL-2-driven activa-
tion of AKT, and depletion or inactivation of ACLY com-
promises IL-2-promoted T-cell growth. Mechanistically,
we demonstrate that ACLY is required for enhancing
histone acetylation levels and inducing the expression
of cell cycle regulating genes in response to IL-2. Thus,
the metabolic enzyme ACLY emerges as a bridge
between cytokine signaling and proliferation of T lym-
phocytes, and may be an attractive candidate target
for the development of more efficient anti-cancer
immunotherapies. Molecular & Cellular Proteomics
15: 10.1074/mcp.M115.057158, 2076–2092, 2016.
The underlying principle of cancer immunotherapy is to
eliminate malignant cells by tuning the immune system (1–2).
This revolutionary way of fighting tumors was originated three
decades ago when a patient suffering from metastatic mela-
noma was treated with the T-cell growth promoting factor
interleukin-2 (IL-2)1 (3). The success of IL-2 administration in
fighting metastatic melanoma demonstrated for the first time
that solely potentiating the activation of T lymphocytes could
abrogate certain human cancers (4). Current immunotherapy
approaches include the use of autologous gene-engineered T
cells that, once expanded ex vivo with IL-2, are re-infused
back into patients by the so-called adoptive cell transfer
therapy (ACT) (5–7). Despite the promising results of this
approach, a safe and long-lasting expansion of transferred T
cells remains a major challenge because of the undesirable
side effects derived from the use of IL-2. Continued exposure
to high doses of IL-2 results in increased susceptibility of T
cells to apoptosis (8). Moreover, IL-2 is also a critical compo-
nent for regulatory T-cell (Treg) development and function
(9–10), and as such it functions as a negative regulator of the
immune response (11). Consequently, although IL-2 consti-
tutes a key component of current immunotherapies, a great
deal of effort is being devoted to the development of novel
strategies that would boost the T-cell immune response more
safely. In this regard, it has been shown that IL-2-related
toxicity can be partially minimized by the use of gene-engi-
neered T cells expressing IL-2 receptor chimeras capable of
transducing signals in the absence of the cytokine (12–13). A
synthetic version of IL-2 with increased affinity for IL-2 recep-
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tor beta chain, named superkine or super-2, has also been
proven to successfully induce the proliferation of cytotoxic T
cells while eliciting a reduced expansion of Treg populations
(14). However, although great improvements have been
achieved since IL-2 was first administered to boost the im-
mune system of a cancer patient, IL-2-related toxicity issues
still persist in current anti-cancer immunotherapies. There-
fore, a deeper understanding of IL-2-mediated regulatory
mechanisms could help to design safer therapies.
Signaling cascades activated in response to IL-2 have been
extensively studied since the late 70s when the cytokine was
discovered (15–17). Antigen binding to the T-cell receptor
promotes IL-2 secretion as well as expression of IL-2 receptor
(IL-2R), which comprises a hetero-oligomeric complex con-
sisting of three polypeptide subunits named ,  and . En-
gagement of IL-2/IL-2R induces receptor oligomerization
which results in the activation of members of the JAK tyrosine
kinase family (18–19). JAK kinases associate with discrete
regions of the IL-2R  and  subunits, thereby phosphory-
lating the receptor and initiating a complex network of down-
stream signaling cascades (20–21). JAK/STAT, RAS/MAPK
and PI3K/AKT pathways are the three main signaling
branches activated upon IL-2 stimulation of T cells that cul-
minate in immune response modulation (22–24). Traditionally,
effectors involved in signal transduction have been analyzed
using classical biochemical methods. However, this approach
is hampered by the limited capacity to analyze biological
systems in their complexity. Signaling pathways are intercon-
nected protein networks, therefore they need to be analyzed
as a whole. In this regard, mass spectrometry (MS)-based
quantitative proteomics/phosphoproteomics has emerged as
a powerful tool to investigate signal transduction cascades
(25–27). In fact, using quantitative mass spectrometry tech-
niques we have elucidated the global tyrosine phosphopro-
teome of IL-2 and IL-15 signaling pathways in T lymphocytes
(28–29).
It has been shown that besides playing a key role in signal
transduction, protein phosphorylation is an essential regula-
tory mechanism altering gene expression (30–31). IL-2-trig-
gered signals are known to be transmitted to the nucleus
leading to changes in gene expression regulation that gener-
ate the adequate cellular response and immune regulation.
For instance, IL-2 treatment results in phosphorylation of
STAT5A, which is a pre-requisite for this transcription factor to
translocate into the nucleus and regulate gene expression
(32–33). Despite its relevance, the precise influence of IL-2 in
the modulation of nuclear phosphorylation and its impact on
cellular proliferation remains obscure. In the present study we
have examined the nuclear phosphoproteome of resting and
IL-2-treated T lymphocytes. We report the identification and
quantification of thousands of site-specific phosphosites,
which represents the largest dataset of nuclear phosphoryla-
tions reported on human CD4 T lymphocytes. Importantly,
over 300 phosphosites were found to be specifically regulated
upon IL-2 stimulation, including Ser455 on ATP-citrate lyase
(ACLY), a metabolic enzyme responsible for generating
acetyl-CoA. By inhibiting or depleting ACLY in T cells we
demonstrate the relevance of this enzyme in IL-2-dependent
modulation of histone acetylation levels and T-cell prolifera-
tion. Moreover, our study provides a collection of candidates
for future hypothesis-driven experiments that could clarify the
regulatory networks that lead to IL-2-triggered expansion of T
cells and may serve as targets for cancer immunotherapy.
MATERIALS AND METHODS
Reagents, Antibodies, Peptides, and Primers—Human recombi-
nant IL-2 was kindly provided by “AIDS Research and Reference
Reagent Program”, Division of AIDS (NIH, National Institute of Health,
Bethesda, MD). The following antibodies from (Cell Signaling, Danver,
MA) were used for Western blotting assays: AKT (#-9272), phospho-
AKT (Ser473) (#-4060), ACLY (#-13390), phospho-ACLY (Ser455) (#-
4331), ERK1/2 (#-9102), phospho-ERK1/2 pThr202/Tyr204 (#-9101),
Histone H3 (#-9715), and phospho-STAT5 (Tyr695) (#-9351). -tubulin
(T6199) was purchased from (Sigma-Aldrich, Copenhaguen, Den-
mark). Anti-acetyl histone H3 (06–599) and anti-acetyl histone H4
(06–598) used for Western blotting and chromatin immunoprecipita-
tion were purchased from (Millipore, Darmstadt, Munich, Germany).
The HPR-conjugated secondary antibodies anti-mouse (NA931) and
anti-rabbit (NA934) were purchased from GE Healthcare. AKT inhib-
itor MK-2206 and HDAC inhibitor SAHA were purchased from (Sell-
eckchem, Munich, Germany) MEK inhibitor U0126 from (Promega,
Madison, WI) and ACLY inhibitor SB-204990 from (Tocris, Bristol,
UK). Information concerning stable isotope labeled (SIL) peptides
purchased for PRM assay and sequences of the qRT-PCR primers as
well as primers used for site-directed mutagenesis are provided in
supplemental Table S1.
Cell culture and stimulation—Human leukemic Kit225 T lympho-
cytes were maintained in RPMI 1640 media (Gibco, Hvidovre, Den-
mark) supplemented with 10% FBS, 1% glutamine, 1% sodium py-
ruvate, 1% penicillin/streptomycin and 16 U/ml of IL-2 at a density of
1.106 cell/ml at 37 °C and 5% CO2. Cell number was estimated using
NucleoCounter (ChemoMetec, Allerod, Denmark). For the large-scale
SILAC experiments, Kit225 T cells were grown in media containing
either the light (Arg0/Lys0) or heavy (Arg6/Lys4) isotopes of lysine and
arginine. Prior to cytokine treatment, cells were IL-2-starved for 48 h
to synchronize them at G1 phase of the cell cycle. Stimulation was
performed by incubating cells with 200 U/ml of IL-2 for 5 min at 37 °C
and rapidly quenched by placing cells on ice and washing with cold
PBS. In the SILAC experiments, T cells grown in light media were kept
unstimulated and served as control whereas heavily labeled Kit225 T
cells were treated with the cytokine.
Human U2OS osteosarcoma cell line was maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum
(FBS).
Plasmids, Cell Transfection and Generation of Stable T-cell Line—
The lentiviral vector pSicoR was obtained from (Addgene, Cambridge,
MA) (Addgene Plasmid 11579) in accordance with Material Transfer
Agreements (MTAs) and the lentiviral vector pCDF1-MCS2-EF1-Puro
was purchased from (System Biosciences Co, Palo Alto, CA). In order
to create a DNA construct for ACLY expression, the pSicoR plasmid
was modified so that the U6-ShRNA cloning cassette was ex-
changed with EF1alpha-eYFP construct by PCR methods and con-
ventional cloning. Simiarly, the CMV-eGFP cassette on the pSicoR
plasmid was exchanged by EF1-Puro cassette from vector pCDF1-
MCS2-EF1-Puro and puromycin resistance gene was substituted
by ORF of ACLY cDNA. ACLY cDNA containing each single point
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mutation of interest was generated by standard site-directed DNA
mutagenesis. The sequences of several clones were verified by
DNA sequencing and error free clones were chosen for transfec-
tions. U2OS cells were transfected using XtremeGENE HD (Roche,
Hvidovre, Denmark) following manufacturers recommendations.
The RNAi sequence potentially targeting human ACLY transcript
was generated using available web resources (http://www.dharmacon.
com) according to published recommendations for siRNA/shRNA
design (34–35). The shRNA sequences were synthesized (DNA tech-
nology, Denmark) as two complementary DNA oligonucleotides:
T(N19)TTCAAGAGA(rN19)TTTTTTC and TCGAGAAAAAA(N19)TCTC-
TTGAA(rN19)A where N19 is the 19-nt sense strand of the target
sequence and rN19 is the complementary antisense strand. The
targeting sequence (N19) we used for silencing ACLY was 5-GGA-
GGAAGGGAATGAAACA-3 whereas the random sequence 5-GCA-
ATATGACGAGTTAGTA-3 was used as control. Annealed oligonu-
cleotides were directly cloned into the lentiviral pSicoR-puro vector
that allows puromycin resistance-based selection of shRNA-express-
ing cells. After DNA constructs were verified, lentiviral particles were
generated as previously described (36). Briefly, HEK-293T cells were
co-transfected with the lentiviral vector and the virus packaging plas-
mids using Metafectene and supernatants were collected 48 h and
72 h postinfection. Then viral particles were concentrated by ultra-
centrifugation and used for infection of Kit225 T cells to generate
stable cell lines expressing the described RNAi constructs.
Nuclear and Phosphopeptide Enrichment—Unstimulated (Arg0/
Lys0) and IL-2-treated (Arg6/Lys4) Kit225 T cells were subjected to
cytosol and nuclear enrichment. Briefly, cells were resuspended in a
lysis buffer (25 mM TrisHCl pH 7.5, 100 mM NaCl, 1% Nonidet P-40,
complete protease inhibitor mixture tablets (Roche) and phospho-
STOP tablets (Sigma-Aldrich), and centrifuged for 15 min at 13,000
rpm. Cytosolic fraction was recovered and nuclei-containing pellet
was disrupted by resuspending in urea buffer (8 M urea, 10 mM
TrisHCl pH 7.5) and sonication. After estimating protein abundance
by BCA method, light and heavy cell lysates were combined in 1:1
ratio according to their protein concentration and subjected to in-
solution digestion using LysC and trypsin as previously described
(37). Proteolytic digestion products were desalted on a Sep-Pak C18
cartridge (Waters, Milford), lyophilized for 2 days and enriched in
phosphopeptides by consecutive incubations with TiO2 beads (38–
39). Half sample of each fraction was directly analyzed by LC-MS/MS
whereas the remaining halves were pooled together and further frac-
tionated using high pH fractionation prior MS analysis (40).
Mass Spectrometry Analysis—Shotgun proteomic analyses were
carried out using a reverse phase liquid chromatography system
(EASY-nLC 1000 ultrahigh pressure, Thermo Fisher Scientific) inter-
faced with a Q Exactive HF mass spectrometer (Thermo Fisher Sci-
entific, Waltham, MA) via a nanoelectrospray source (Thermo Fisher
Scientific). Acidified peptides were loaded on an analytical in-house
packed column (20 cm 75 m, ReproSil-Pur C18-AQ 3 m resin (Dr.
Maisch GmbH)) in solvent A (0.5% acetic acid) and eluted by a
nonlinear 120 min solvent B gradient (0.5% acetic acid, 80% aceto-
nitrile) at a flow rate of 250 nl/min. Q Exactive was operated in a top
10 data dependent mode. Survey scans were acquired at a resolution
of 70,000 (m/z 400) and fragmentation spectra at 35,000 (m/z 400).
Precursors were fragmented by higher energy C-trap dissociation
(HCD) with normalized collision energy of 25 eV. The maximum injec-
tion time was 120 ms for survey and 124 ms for MS/MS scan whereas
the AGC target values of 1e6 and 1e4 were used for survey scans and
for MS/MS scans, respectively. Repeated sequencing of peptide was
minimized by excluding the selected peptide candidates for 45 s.
All raw data files acquired were searched against the UniProt
human database version 2014.01 (with 88,479 sequence entries) with
MaxQuant proteomics computational platform version 1.3.0.5 and
using Andromeda search engine (41). SILAC doublets were selected
for the analysis where light and heavy labels were set as Arg0/Lys0
and Arg6/Lys4. Precursor and fragment mass tolerances were set to
7 and 20 ppm, respectively. Enzyme specificity was set to trypsin,
allowing for cleavage N-terminal to proline and between aspartic acid
and proline (with a maximum of 2 missed cleavages). Carbamidom-
ethylation of C was set as fixed modification whereas oxidation of M,
protein N-terminal acetylation, NQ deamidation and STY phosphory-
lation were selected as variable modifications for database searching.
For the analysis of phosphopeptides, 1% FDR, a minimum localiza-
tion probability of 0.75 and a score difference of at least 5 was used
(42). The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via PRIDE partner repository (43–
44) with the data set identifier PXD002839.
PRM analyses were performed using a Q Exactive mass spectrom-
eter (ThermoFisher Scientific) interfaced with an Easy-nLC 1000
nanoUPLC System (ThermoFisher Scientific). Phosphopeptides were
air dried in a Speedvac and resuspended with the SIL phosphopep-
tide mixture. Samples were loaded onto an Acclaim PepMap100
precolumn (75 m  2 cm, ThermoFisher Scientific) connected to an
Acclaim PepMap RSLC (50 m 15 cm, Thermo Scientific) analytical
column. Peptides were eluted with a 90 min linear gradient from 3%
to 30% of acetonitrile in 0.1% of formic acid at a flow rate of 300
nl/min directly onto the nanoES Emitter (ThermoFisher Scientific). The
Q Exactive was operated in Targeted-MS2 mode and method opti-
mization was achieved by analysis of SIL phosphopeptide by Full MS,
Full MS/dd-MS2 (Top10) and Targeted-MS2. Then, selected m/z val-
ues were incorporated in an inclusion list and specific retention time
windows were applied based on method optimization results. Spectra
were acquired at a resolution of 17,500 (m/z 200). Peptide selection
was done with an isolation window of 2.0 Th and normalized collision
energy of 28 was applied for peptide fragmentation. The maximum
injection time was 500 ms and an AGC target value of 5e5 was used.
For peptide relative quantification Skyline v2.6.0.6851 software was
used (45). All integrated peaks were manually inspected to ensure
correct peak detection and total peak area values were exported into
Microsoft Office Excel (Microsoft) for further data analysis.
Flow Cytometry—For cell proliferation assays, Kit225 T cells were
incubated with 2.5 M carboxyfluorescein diacetate succinimidyl es-
ter (CFSE) (ThermoFisher Scientific) and U2OS cells with 0.5 M
CellTrace Far Red™ (CTFR) (ThermoFisher Scientific) for 15 min at
37 °C. Cells were washed with complete medium for 20 min, treated
and cultured as indicated and finally fixed for 10 min in a solution of
buffered formaldehyde (3.7%). Only YFP-expressing U2OS cells were
selected for the dye dilution analysis and hence, estimation of the
proliferation index. To assess cell cycle distribution, Kit225 T cells
were fixed with chilled 70% ethanol and stained with 50 g/ml pro-
pidium iodide. In both type of experiments fluorescence was detected
using a FACSCalibur (BD Biosciences, San Jose, CA) flow cytometer.
Proliferation Wizard software was used to identify cells in different
generations and calculate the Proliferation Index whereas Summit 4.3
software was used to perform the cell cycle distribution analysis.
Crystal Violet Staining—U2OS cells were fixed for 10 min (buffered
formaldehyde 3.7%), washed with PBS and subsequently stained
with a 0.25% crystal violet solution. After removing excess stain,
crystal violet was dissolved in 2% SDS solution for 30 min. The optical
density of the extract was read with a spectrophotometer at 546 nm.
Acid Extraction of Histones—Cell pellets were resuspended in
complete hypotonic buffer (10 mM Hepes, 10 mM KCl, 1.5 mM MgCl2,
0.5 mM DTT and phosphatase inhibitors and protease inhibitor mix-
ture) supplemented with H2SO4 to a final concentration of 1% and
incubated for 30 min at 4 °C with rotation. Samples were centrifuged
for 10 min at 11,000 rpm at 4 °C and supernatant was collected to
further precipitate protein by adding trichloroacetic acid (TCA) to 33%
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final concentration and incubating for 10 min at 4 °C. Following 5 min
centrifugation at 14,000 rpm at 4 °C, pellets were washed twice with
acetone and after allowing drying they were resuspended in MilliQ
water.
Chromatin Immunoprecipitation (ChIP) Analyses—ChIP analyses
were performed following previously published protocols with minor
modifications (46–47). Briefly, differentially treated Kit225 T cells
were crosslinked using formaldehyde and lysed. Nuclei were col-
lected and subjected to sonication to fragment chromatin. DNA was
immunoprecipitated using anti-H3 and anti-H4 antibodies and en-
riched chromatin was quantified by real-time PCR in the Applied
Biosystems 7000 Real-Time PCR System using Power SYBR Green
PCR Mastermix (Applied Biosystems).
Immunobloting—Equal amounts of protein lysates were loaded
onto a precast gradient NuPAGE 4–12% Bis-Tris Gel (Invitrogen,
Brondby, Denmark) and transferred into a nitrocellulose membrane
using a semi-dry system. Membranes were blocked with 5% BSA in
TTBS, incubated with the corresponding antibody overnight at 4 °C,
washed prior incubation with the secondary antibody. Finally, ECL
Western blotting detection reagents (PRN2106, GE Healthcare,
Brondby, Denmark) and autoradiography films were used together
with a Kodak Image Station 1000 to visualize the protein of interest.
The intensity of the bands was quantified using ImageJ software
(National Institutes of health, Bethesda, MD).
Gene Expression Analyses—Total RNA was prepared as previously
described (48). Briefly, RNA was purified from Kit225 T cells using
TRIzol (Invitrogen) according to manufacturers instructions. cDNA
was synthesized from 1 g of total RNA by incubating with a reaction
mixture containing 0.25 g of random hexamers and 1 mM dNTP mix
for 5 min at 65 °C followed by 1h incubation at 37 °C with Invitrogen
1st Strand Buffer, 10 mM dithiothreitol and 12 units of M-MLV reverse
transcriptase (Promega). Prior PCR analysis samples were diluted
with 200 l of sterile MilliQ water. For mRNA expression analysis,
cDNA was amplified in the Stratagene Mx3000P System using
SYBR Green JumpStart Taq Ready Mix (Sigma-Aldrich) and quan-
tified using Stratagene MxPro. Amplification of -actin was used for
normalization.
Bioinformatic Analyses—The Perseus software was employed for
the calculation of the statistical significance B, a p value that depends
on protein intensities and ratios. It was also used to perform the
hierarchical clustering analysis. DAVID functional annotation tool (49)
was used to detect the overrepresented gene ontology (GO) terms
“cellular compartment” and “biological process” within the nuclear
phosphoproteome of Kit225 T cells and IL-2-regulated phosphopro-
teins. Overrepresented phosphorylation motifs were searched by
MotifX (50) using a sequence window of 6 residues adjacent to the
phosphorylated amino acid. Then, NetworKIN algorithm (51) version
3.0 was used to predict the kinases responsible for phosphorylating
the defined motifs. For each motif, the frequency of putative kinases
was calculated discarding the kinases predicted to phosphorylate
less than 5% of the sites sharing a motif. Finally, the frequency of
each kinase was normalized to the most frequently occurring kinase
for each motif.
Experimental Design and Statistical Rationale—To define the nu-
clear phosphoproteome of resting and IL-2-treated T cells we ana-
lyzed three biological replicas that were separately SILAC-labeled,
stimulated, processed and finally analyzed by LC-MS/MS. Acquired
raw files were searched using the MaxQuant version 1.3.0.5 and
specifying the raw files that corresponded to each replica. Data was
filtered by FDR  1% and only the phosphosites displaying a local-
ization probability above 0.75 and a score difference of at least 5 were
considered as confident phosphorylated sites (Class I sites). From
those, the phosphosites that were quantified in two out of the three
biological replicas were analyzed using the Perseus software to cal-
culate their statistical significance B value, a p value that depends on
phosphopeptide intensities and ratios. We considered as IL-2-de-
pendent phosphosites the ones that were consistently regulated (IL-
2/Ctr  2 or IL-2/Ctr  0.5 and Significance B p value 0.05) in at least
two out of the three replicas performed. Proliferation experiments
were performed at least three times and statistical analysis was
performed using the Students t test.
RESULTS
Defining the Nuclear Phosphoproteome of CD4 T lympho-
cytes—IL-2 signaling pathways converge into the nucleus to
regulate gene expression and generate an adequate cellular
response. Thus, a precise knowledge of the molecular mech-
anisms orchestrated in the nucleus of IL-2-treated T cells is
essential for the better understanding of the molecular actions
of the cytokine in CD4 T lymphocytes. For that reason, we
characterized on a global scale the IL-2-mediated regulation
of nuclear function. We conducted an unbiased phosphopro-
teomic study based on the identification of site-specific phos-
phorylation events occurring primarily in the nucleus of resting
and IL-2-treated Kit225 human T lymphocytes (Fig. 1A). Pro-
teins were extracted from the nuclear-enriched fraction of
SILAC-labeled T cells that were kept unstimulated (Arg0/Lys0)
or were stimulated with IL-2 (Arg6/Lys4) for 5 min. Protein
extracts derived from both conditions were combined at a 1:1
ratio according to protein concentration, digested with tryp-
sin, and the resulting peptides were enriched in phosphopep-
tides using TiO2 beads prior to mass spectrometry (MS) anal-
ysis. We performed three biological replicates resulting in the
identification of a total of 12,250 phosphorylated sites. Of
these, 8521 could be confidently assigned to a specific posi-
tion within a protein (median localization probability and score
difference 0.999 and 35, respectively) (Fig. 1B). The 8,521
class I sites are comprised mainly by serine phosphorylations
(pSer) although we also detected numerous phosphothreo-
nine (pThr) and phosphotyrosine (pTyr) residues (Fig. 1C and
supplemental Table S2). The majority of phosphosites that we
identified have already been described and are reported in
PhosphoSitePlus database. However, we now present evi-
dence that a large number of phosphosites reported only in
mice or rats in the database are also present in humans
(termed as “by homology” in Fig. 1D). Furthermore, our study
has identified many previously unreported phosphorylation
sites (Fig. 1D), which represent a valuable source of novel
information to understand the role of phosphorylation events
in the nucleus of T lymphocytes.
The 8521 class I sites detected in this study correspond to
3032 distinct gene products. These phosphoproteins were
functionally classified by Gene Ontology (GO) analysis aiming
to detect the most significantly enriched terms within the
“Cellular Compartment” and “Biological Process” categories.
Regarding the cellular compartment category, most of the
phosphoproteins that we report belong to distinct nuclear
localizations such as nuclear lumen, nucleolus or nuclear
envelope, consistent with the aim of our study focused on
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depicting the nuclear phosphoproteome of T lymphocytes.
Moreover, the spliceosome and histone acetyltransferase
complexes were also highly enriched within our dataset of
lymphocytic phosphoproteins (Fig. 1E). In line with these re-
sults, various biological processes related to key nuclear
functions such as gene transcription and cell cycle regulation
were significantly overrepresented among the phosphopro-
teins in our dataset (Fig. 1F).
IL-2-induced Changes in the Nuclear Phosphoproteome of
T Cells—From the collection of unique class I phosphosites
identified, a total of 8215 could be quantified and displayed a
SILAC IL-2/control ratio. For subsequent analyses, we fo-
cused on 6145 phosphosites, which could be quantified in at
least two out of the three biological replicates that we per-
formed (Fig. 2A–2B, supplemental Table S3). These phospho-
sites belong to 2,382 proteins that were mainly monophos-
phorylated, although we also detected numerous nuclear
proteins that were phosphorylated on multiple residues in
Kit225 T lymphocytes (Fig. 2C).
For deciphering IL-2-dependent nuclear phosphorylation
events we only considered those sites that were consistently
regulated (IL-2/Ctr ratio  2 or IL-2/Ctr ratio  0.5 and Sig-
nificance B p value  0.05) in at least 2 out of the three
replicates. Following these criteria, we found that IL-2 triggers
the phosphorylation of 331 sites and the de-phosphorylation
of 59 sites (Fig. 2D, supplemental Table S4). Selected IL-2-
dependent phosphorylations were validated by parallel reac-
tion monitoring (PRM)-based targeted proteomics (supple-
mental Fig. S1). Several of the phosphorylation sites that are
known to be induced upon IL-2 stimulation of T cells were
also detected in our study, thus validating our approach (Ta-
ble I). This is the case of STAT5A (Ser780/Tyr694), the two main
representatives of the MAPK signaling cascades, MAPK1
(Thr185/Tyr187) and MAPK3 (Thr202/Tyr204), and AHNAK
(Ser135) (28, 32–33, 52–53).
However, the majority of IL-2-regulated phosphosites identi-
fied in this study have not been described previously. In addi-
tion, we identified a large number of multiply phosphorylated
proteins highlighting the complex regulation exerted by IL-2 on
individual nuclear proteins in T lymphocytes (Fig. 2E).
Gene Ontology analysis of IL-2-regulated phosphoproteins
in Kit225 T cells revealed that biological processes related to
FIG. 1. Nuclear phosphoproteomic analysis of CD4 T lymphocytes. A, Flow diagram of the MS-based quantitative phosphopro-
teomic strategy followed. B, Number of unique Class I phosphosites (p-sites) and corresponding proteins quantified in the three individual
biological replicates. C, Distribution of all quantified phosphorylated serine, threonine and tyrosine residues. D, Proportion of phosphor-
ylated sites reported or not in PhosphoSitePlus database. Gene Ontology analysis indicating the Cellular compartments (E) and biological
processes (F) overrepresented within the phosphoproteome of CD4 T lymphocytes. The fold enrichment and the statistical significance
p value of the most indicative terms are indicated. The size of the dots correlate with the number of proteins grouped in the same term.
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gene expression and cell cycle regulation are the most highly
enriched terms, in line with the documented pro-proliferative
function of IL-2 (Fig. 2F). Our dataset of IL-2-modulated phos-
phoproteins includes several transcription factors (supple-
mental Table S5) as well as numerous enzymes involved in
chromatin remodeling. We found that the phosphorylation
status of several residues corresponding to histone methyl-
transferases and demethylases was increased upon IL-2
stimulation of T cells (Table II). Additionally, we detected
differentially regulated phosphosites corresponding to distinct
histone acetyltransferases (HAT) whereas the overall phos-
phorylation status of histone deacetylases (HDAC) seemed to
be unaltered upon IL-2 stimulation in Kit225 T cells (Table II and
supplemental Table S6). Altogether, our data indicate that nu-
clear events triggering IL-2-mediated T-cell proliferation are
readily induced following 5 min of stimulation with the cytokine.
FIG. 2. Nuclear phosphoproteome in resting and IL-2-stimulated T lymphocytes. A, Overlap between the p-sites quantified in the three
biological replicates performed. B, Number of unique p-sites and phosphoproteins overlapping between the different replicates. C, Distribution
of number of p-sites identified and quantified for each phosphoprotein. D, Overall IL-2/Ctr SILAC ratio as a function of phosphopeptide
intensity. In blue and red are indicated the p-sites down-regulated and up-regulated by IL-2, respectively. The MS spectra of ZNF292 pThr1017
and STAT5A pTyr694-bearing peptides that are down-regulated and up-regulated upon IL-2 stimulation respectively are shown. E, Phospho-
proteins containing regulated p-sites may also have non-regulated sites. The size of the dots represents the amount of proteins following the
same regulation. F, Biological processes over-represented among phosphoproteins with IL-2-regulated p-sites.
ACLY Plays a Pivotal Role in IL-2-mediated T-cell Growth
Molecular & Cellular Proteomics 15.6 2081
To have a better understanding of the mechanisms leading
to changes in the nuclear phosphoproteome of IL-2-treated T
cells, we searched for the presence of overrepresented linear
kinase motifs within IL-2-modulated phosphosites. We pro-
cessed all phosphopeptide sequences bearing the IL-2-mod-
ulated phosphosite (pThr/pSer  6 aa) using MotifX software
and detected five significantly enriched pSer motifs and a
single pThr motif (Fig. 3A). The sequence logos of the two
most enriched motifs (.R.R…… and …RR.S…) and of the
most abundant motif (……SP….) among IL-2-dependent
phosphosites are shown in Fig. 3B. To identify the putative
kinases responsible for the phosphorylation of those motifs,
all phosphopeptide sequences sharing the same linear kinase
motif were examined using the NetworKIN software. The anal-
ysis revealed that the phosphoserine motifs in which the
modified residue is preceded by a single basic amino acid are
likely to be phosphorylated by protein kinase C beta (PKC)
and CDC-like kinase 1 (CDK1) (Fig. 3A). The most enriched
basic motifs (.R.R..S…… and …RR.S……) were predicted to
be targeted among others, by the AKT, mTOR, p70S6 kinase
and the ribosomal protein S6 kinase alpha-1 (RSK1) which are
downstream effectors of the PI3K and MAPK signaling path-
ways (54–55). Additionally, the proline-directed kinases
MAPK1/3 and CDK1/2 were predicted to phosphorylate the
majority of the IL-2-regulated phosphosites (31%). Given that
the two key residues modulating the activity of MAPK1 and
MAPK3 are phosphorylated in our nuclear samples of IL-2
stimulated T cells (Table I), most phosphorylation events trig-
gered by IL-2 in the nucleus of CD4 T lymphocytes appear to
be conducted by members of the MAPK family. Furthermore,
our data set includes hundreds of other kinases and phos-
phatases that may also contribute to IL-2-driven nuclear
phosphorylation events (Table III and supplemental Table S3).
ACLY, a Novel Target of IL-2-driven Phosphorylation—Most
of the IL-2-regulated phosphosites reported in this study have
never been shown to be modulated by the cytokine. Hence,
corresponding phosphoproteins are putative candidates to
participate in IL-2-dependent T-cell responses. We focused
our attention on ACLY (ATP-citrate lyase) whose phosphory-
lation levels appeared to be regulated by IL-2 (Fig. 4A). ACLY
is an acetyl-CoA generating enzyme that is thought to play a
key role in the proliferation of tumor cells (56–57). However,
the contribution of this enzyme to IL-2-triggered T-cell growth
is unknown. We identified three phosphorylation sites on the
central region of ACLY: pSer455 and pSer481, which precede
the CoA binding domain, and pSer646, located between the
TABLE I
Known IL-2-induced phosphorylation sites. Positions of phosphosites are presented according to Uniprot number and the phosphorylated
residue is highlighted in bold within the sequence window
Protein Uniprot ID Modifiedresidue
Normalized IL-2/Ctr
ratio Sequence window
(6aa)
Rep1 Rep2 Rep3
MAPK1 P28482 Tyr187 17.64 15.68 7.23 TGFLTEYVATRWY
Thr185 8.95 9.21 9.74 DHTGFLTEYVATR
MAPK3 P27361 Thr202 10.45 10.40 4.61 DHTGFLTEYVATR
Tyr204 6.48 9.18 4.61 TGFLTEYVATRWY
STAT5A P42229 Tyr694 7.59 10.12 6.29 AKAVDGYVKPQIK
Ser780 2.19 2.11 – SLDSRLSPPAGLF
AHNAK Q09666 Ser135 4.38 4.22 3.89 IKPRLKSEDGVEG
TABLE II
IL-2-modulated enzymes involved in chromatin remodelling. Positions of phosphosites are presented according to Uniprot number and the
phosphorylated residue is highlighted in bold within the sequence window
Protein Uniprot ID Modifiedresidue
Normalized IL-2/Ctr
ratio Sequence window
(6aa)
Rep1 Rep2 Rep3
Histone lysine N-methyltransferases MLL Q03164-3 Ser261 11.33 5.51 – KIKRTPSATFQQA
Ser2152 3.45 3.83 – PRIRTPSYSPTQR
Ser2199 3.14 3.03 – IGSRRHSTSSLSP
Ser3039 2.57 2.35 3.17 GLQVPVSPTVPIQ
MLL2 O14686-3 Ser2277 3.03 2.74 – ASEPLLSPPPFGE
WHSC1L1 Q9BZ95 Thr456 3.55 3.74 – HSQRRHTSAEEEE
Lysine-specific demethylases PHF2 O75151 Ser655 2.87 2.85 2.05 ALRPPTSPGVFGA
Ser705 11.81 9.72 8.48 APKRDLSFLLDKK
Ser899 3.27 2.80 – SKKRKGSDDAPYS
Ser929 3.54 2.28 – EGTRVASIETGLA
KDM3B Q7LBC6 Ser798 5.20 6.08 4.29 EAVKRFSLDERSL
Histone acetyltransferases KAT6A Q92794 Ser941 4.63 3.82 – LPKRRLSEGVEPW
KAT7 O95251 Ser50 2.72 2.59 – RSSARLSQSSQDS
Ser57 0.15 1.04 0.15 QSSQDSSPVRNLQ
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CoA binding and ligase CoA domains (Fig. 4A). Importantly,
this is the first study demonstrating that ACLY Ser646 can be
phosphorylated in CD4 T cells. The precise assignment of
the newly identified phosphosite was verified by manual an-
notation of the fragmentation spectra (supplemental Fig. S2).
Our analysis revealed that, whereas pSer481 and pSer646 re-
main unaffected by cytokine treatment, phosphorylation on
ACLY Ser455 is induced in IL-2-treated T lymphocytes (Fig.
4B). IL-2-dependent up-regulation of ACLY pSer455 was con-
firmed by PRM-based targeted proteomics (Fig. 4C, supple-
mental Fig. S3). Because phosphorylation of Ser455 has been
shown to stimulate the enzymatic activity of ACLY (58), our
results suggest that treatment of T lymphocytes with IL-2
triggers functional activation of ACLY.
FIG. 3. Linear phosphorylation motif analyses of IL-2-regulated nuclear phosphoproteome. A, Significantly overrepresented linear
motifs (middle) were identified by MotifX and then, motifs were matched to putative kinases using NetworKIN (left). Fold enrichment and
number of p-sites showing the same linear motif are also indicated (right). B, The two most enriched (.R.R..S…… and…RR.S……) and the most
abundant (…..SP….) phosphorylation motifs among regulated p-sites.
TABLE III
IL-2-regulated serine/threonine kinases and phosphatases. Positions of phosphosites are presented according to Uniprot number and the
phosphorylated residue is highlighted in bold within the sequence window
Protein Uniprot ID Modifiedresidue
Normalized IL-2/Ctr
ratio Sequence window
(6aa)
Rep1 Rep2 Rep3
Ser/Thr kinases MAPK1 P28482 Tyr187 17.64 15.68 7.23 TGFLTEYVATRWY
Thr185 8.95 9.21 9.74 DHTGFLTEYVATR
MAPK3 P27361 Thr202 10.45 10.40 4.61 DHTGFLTEYVATR
Tyr204 6.48 9.18 4.61 TGFLTEYVATRWY
CDKL5 O76039 Ser407 2.46 2.39 2.64 NIPHLLSPKEAKS
SRPK2 P78362–2 Ser391 2.58 3.45 – DPTWIESPKTNGH
PRKG1 Q13976–2 Thr532 – 0.25 0.45 FGKKTWTFCGTPE
PRKAR2B P31323 Ser114 0.27 0.20 – RFTRRASVCAEAY
CDK13 Q14004 Ser1054 0.38 0.55 0.30 SLGLDDSRTNTPQ
Ser/Thr phosphatases PPP1R10 Q96QC0 Ser313 2.19 2.13 2.66 KKKKVLSPTAAKP
CTDSPL2 Q05D32 Ser28 7.14 7.23 – RAKRKYSEVDDSL
PPP1R12A O14974 Ser507 5.42 4.39 – IPRRLASTSDIEE
SSH1 Q8WYL5 Ser897 5.73 4.19 – EGGSLKSPPPFFY
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ACLY has been traditionally considered a cytosolic enzyme,
although it was recently found in the nucleus of several types
of mammalian cells as well (59). Our large-scale phosphopro-
teomic analysis using a nuclear-enriched fraction of T cells
also suggested that ACLY could be present in the nucleus of
CD4 T lymphocytes. To confirm this, we followed an exhaus-
tive nuclear enrichment protocol and investigated the pres-
ence of ACLY by Western blotting both in the nuclear and
cytosolic fractions obtained from resting or IL-2-treated T
cells. As shown in Fig. 4D, ACLY could be clearly detected in
the nucleus and cytoplasm of Kit225 T cells independently of
the stimulus. Importantly, ACLY phosphorylation on Ser455
was nearly undetectable in cytokine-starved T cells but was
induced upon 5 min of stimulation with IL-2. In addition, we
monitored the dynamics of ACLY pSer455 and showed that
IL-2-induced phosphorylation of this site reached the maxi-
mum level after 20 min of stimulation both in the nucleus and
cytoplasm and decreased subsequently (Fig. 4D).
FIG. 4. Characterization of IL-2-induced ACLY phosphorylation. A, Graphical representation of ACLY. The localization and sequence of
the three phosphopeptides quantified in this study are indicated. B, IL-2/Ctr SILAC ratios obtained for each ACLY phosphopeptide in the three
biological experiments. C, PRM-based validation of IL-2-induced phosphorylation of ACLY Ser455. D, Time-dependent phosphorylation of
nuclear and cytoplasmic ACLY in response to IL-2 stimulation. E, IL-2 dose-dependent response of ACLY pSer455. F, IL-2-induced pSer455 on
ACLY is mediated by AKT.
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To characterize further the regulation mediated by IL-2 on
ACLY we performed a dose-dependent assay. We found that
ACLY pSer455 is significantly induced in T cells treated with a
saturating IL-2 concentration (6.25 nM) coinciding with the
activation of the MAPK (or ERK) and PI3K signaling networks,
as shown by the increased phosphorylation of their represent-
ative effectors MAPK1/3 and AKT, respectively (Fig. 4E). To
disclose if any of these two signaling pathways is respon-
sible for mediating IL-2-induced phosphorylation of ACLY, T
cells were pre-treated with several concentrations of U0126
and MK-2206, specific inhibitors of MEK1/2 and AKT, re-
spectively, and subsequently stimulated with IL-2. As
shown in Fig. 4F, U0126 dramatically hampered IL-2-in-
duced phosphorylation of MAPK1/3 or ERK1/2 without al-
tering the phosphorylation status of ACLY. By contrast,
pre-treatment with the AKT inhibitor resulted in a reduction
of AKT phosphorylation and a notable decrease in IL-2-
triggered ACLY pSer455. Altogether, our data indicate that
phosphorylation of ACLY Ser455 is mediated by IL-2-in-
duced activation of AKT.
ACLY Plays a Key Role in IL-2-dependent Proliferation of
Kit225 T Cells—We and others have previously demonstrated
that IL-2, or its closely related family member IL-15, is re-
quired for promoting the proliferation of Kit225 T cells (29, 53).
In the present study we aimed to investigate the role of ACLY
in IL-2-mediated T-cell growth. We generated a stable Kit225
T-cell line with efficient shRNA-mediated suppression of
ACLY and a control cell line (Fig. 5A). Both were deprived of
IL-2 for 2 days and then maintained in the presence of the
cytokine for an additional 48 h. After this period, cell number
was estimated. As shown in Fig. 5B, ACLY-depleted cells
grew significantly less than control T lymphocytes. A similar
effect was observed by estimating T-cell proliferation index by
flow cytometry using the intracellular fluorescent dye CFSE,
which is diluted twofold with each cell division. Proliferation of
shACLY-expressing Kit225 T cells was clearly hampered in
comparison to control cells 48 h after re-introduction of the
cytokine, an effect that was even more dramatic 72 h after
cytokine addition (Fig. 5C). To strengthen these data pointing
to ACLY as a relevant mediator of IL-2-induced T-cell prolif-
eration, we carried out additional experiments using a com-
mercially available ACLY inhibitor (SB-204990). In agreement
with the data gathered with shACLY, cell counting assay
showed that T cells cultured with IL-2 in the presence of the
ACLY inhibitor lack the capacity to proliferate (Fig. 5D). More-
over, CFSE-based flow cytometry analysis showed that the
inhibitor dramatically compromised the capacity of the T lym-
phocytes to respond to IL-2 in a dose-dependent manner (Fig.
5E). Altogether, these results indicate that functional ACLY is
required for Kit225 T cells to proliferate in the presence of
IL-2.
We next tested the impact of ACLY phosphorylation in
cellular proliferation. We expressed YFP-ACLY Ser455 phos-
phomimetic Ser455Asp (S455D) or Ser455Glu (S455E) and
phosphomutant Ser455Ala (S455A) proteins in U2OS cells.
Transfected cells were grown in the presence of the AKT
inhibitor MK-2206 for 24 h and subsequently the proliferation
index of YFP U2OS cells was estimated by dye dilution
assay using flow cytometry. As shown in Fig. 5F, ACLY
S455D- and S455E-expressing cells proliferated significantly
more than ACLY S455A-expressing cells. Accordingly, crystal
violet staining revealed that ectopic expression of phosphor-
ylation-mimicking mutants (ACLY S455D and S455E) promote
higher cellular proliferation rates relative to the expression of
ACLY S455A (Fig. 5G). These results suggest that ACLY is a
relevant downstream effector of AKT involved in promoting
the proliferation of cells.
To examine further the effect of ACLY depletion or inhibition
in cellular proliferation, we monitored the distribution of cell
cycle phases in Kit225 T cells. As expected, cytokine deprived
T cells were arrested in the G1 phase of the cell cycle (G1
82%; S 9%; G2/M 7%) and entered the S phase 24 h after
addition of IL-2 (G1 46%; S 41%; G2/M 12.5%) (Fig. 6A). By
contrast, in the presence of ACLY inhibitor fewer cells could
enter S phase, an effect that was more dramatic as the
concentration of the inhibitor increased. In agreement with
these results, we observed that the expression of several key
regulators of the G1/S transition such as CDC25, CDK1, E2F2
and cyclin A (CYCA) was induced in IL-2-treated T cells but
dramatically reduced in cells treated with the ACLY inhibitor
(Fig. 6B). Collectively, our data show that inhibition of ACLY
compromises IL-2-induced T-cell proliferation by reducing the
expression of key genes required for G1/S transition of the cell
cycle.
ACLY Influences Histone Acetylation Levels on CD4 T
lymphocytes—Acetyl-CoA is impermeable to membranes and
consequently it is assumed that it is generated in the same
subcellular compartment where it is required. Given the nu-
clear localization of ACLY in Kit225 T lymphocytes, we pos-
tulated that this enzyme could be a source of acetyl-CoA in
the nucleus of IL-2-treated T cells. We observed that IL-2
stimulation leads to an increase in global acetylation of both
histone 3 and 4 (H3 and H4) in human T lymphocytes (Fig. 7A).
The increase in H4 acetylation observed is in line with the data
presented by Taplick and colleagues showing that IL-2 pro-
motes changes in the acetylation of H4 in murine T cells
deprived of IL-2 (60). More interestingly, we found that IL-2-
induced H3 and H4 acetylation was dramatically reduced
upon inhibition of ACLY (Fig. 7A), suggesting that ACLY is a
key player modulating histone acetylation in IL-2-treated T
lymphocytes.
It is assumed that histone acetylation renders chromatin
more accessible to nuclear factors, leading to enhanced gene
expression (61–62). We aimed to determine if the impaired
gene expression detected upon ACLY inhibition (Fig. 6B)
could be explained by alterations in promoter histone acety-
lation levels. Using chromatin immunoprecipitation assays,
we observed that H3 and H4 acetylation was increased on the
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promoters of CDC25, CDK1, E2F2, and CYCA upon IL-2
stimulation. By contrast, the acetylation levels of H3 and H4
were significantly reduced in these four promoters upon ACLY
inhibition (Fig. 7B). These results correlate well with gene
expression data presented above. Altogether, we provide ev-
idence indicating that ACLY is involved in modulating histone
FIG. 5. ACLY activity is required for IL-2-triggered T-cell proliferation. A, Western blot showing total levels of ACLY in shCtr- and
shACLY-expressing cells. B, Cell number was estimated in control and ACLY silencing Kit225 cells deprived with IL-2 and 48 h after
re-introduction of the cytokine. C, Resting shCtr- and shACLY-expressing cells were stained with CFSE and cultured with IL-2 up to 48 h and
72 h. Then fluorescence was measured by flow cytometry and Proliferation Wizard software was used to calculate the proliferation index. D,
Kit225 T-cell number was estimated in IL-2-deprived and IL-2-treated T cells that were grown in the absence or presence of the ACLY inhibitor.
E, Proliferation index of Kit225 T cells cultured with IL-2 in the absence or presence of increasing concentrations of ACLY inhibitor for 2 days
was estimated using CFSE dye dilution method. F, Proliferation index of YFP-ACLY phosphomimetic Ser455Asp (S455D) and Ser455Glu (S455E)
and phosphomutant expressing U2OS cells in the presence of 5 M AKT inhibitor was estimated by flow cytometry; mean  S.D. of triplicates
(*, p  0.05). G, Images of crystal violet stained U2OS cells transfected with the indicated YFP-ACLY mutant and cultured in the presence of
5 M AKT inhibitor. Relative quantification of the optical density is also shown; mean  S.D. of triplicates (**, p  0.0005; ***, p  0.0001).
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acetylation levels that result in induction of gene expression to
promote IL-2-dependent T-cell growth.
DISCUSSION
IL-2-induced proliferation of T lymphocytes is vital in the
generation of the immune response and a key process in
current anti-cancer immunotherapy (63–64). Nevertheless,
IL-2 administration is usually accompanied by severe side
effects and it is considered that a more detailed knowledge of
IL-2-dependent signaling events should help improve the ex-
isting anti-cancer therapies. We have evaluated the nuclear
phosphoproteome of resting and IL-2-treated T lymphocytes
to gain an insight into the phosphorylation events occurring in
the nucleus of T cells upon IL-2 stimulation. We report the
identification of a large number of IL-2-regulated phospho-
proteins, including the metabolic enzyme ACLY. Importantly,
we present mechanistic evidence suggesting that ACLY is a
crucial player in IL-2-induced T-cell proliferation.
Our nuclear phosphoproteomic screen has uncovered over
8000 phosphosites, including many previously not reported
ones and thus, represents the most extensive phosphopro-
teomic screen performed to date in CD4 T lymphocytes. In
addition, applying a SILAC-based quantification strategy al-
lowed us to discern between IL-2-dependent and -independ-
ent phosphorylation events. In agreement with most differen-
tial phosphoproteomic studies performed to date the vast
majority of phosphosites detected were not affected by cyto-
kine stimulation, but they could nevertheless play a role in
T-cell biology. This could be the case of constitutive phos-
phorylations on histone deacetylases (HDACs). Indeed, Na-
varro and colleagues demonstrated that basal serine-threo-
nine phosphorylations on HDACs play a central role in
dictating the capacity of cytotoxic T lymphocytes (CTL) to
respond to T-cell receptor (TCR) signaling (65). Interestingly,
phosphorylation status of HDACs also remains unaffected by
IL-2 stimulation (supplemental Table S7), although their role in
T-cell fate has not been examined in the present work.
Without underestimating the relevance of basal phosphor-
ylations, we focused our efforts on characterizing the fraction
of phosphosites that was modulated by IL-2. We detected five
times more phosphosites that were up-regulated by IL-2 rel-
ative to those down-regulated by the cytokine. A similar dis-
tribution was observed upon TCR engagement on CTLs (65).
Kinase prediction tools anticipated that the majority of the
IL-2 induced phosphosites detected were likely to be phos-
phorylated by members of the MAPK family, which we found
phosphorylated and therefore activated. Although MAP ki-
FIG. 6. Inhibition of ACLY results in G1/S cell cycle arrest. A, Cell cycle distribution analysis of Kit225 T cells supplemented with IL-2 in
the absence or presence of indicated concentration of ACLY inhibitor. B, mRNA expression levels of the genes (CDC25, CDK1, E2F1 and
CYCA) was measured by qRT-PCR in control and IL-2-treated T cells that were or were not simultaneously treated with the ACLY inhibitor.
Results were normalized against the expression levels of actin.
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nases also become active upon TCR engagement, Navarro
and co-workers showed that TCR-induced phosphorylations
do not depend so much on MAPK activity, unveiling a relevant
difference between TCR and IL-2 mediated phosphorylations
(65). In addition, the phosphorylation status of certain chro-
matin re-modeling factors is also differentially affected upon
stimulation of TCR or IL-2R. For instance, CBX3 Ser93 be-
comes phosphorylated in IL-2-treated CD4 T cells but not in
CTLs (66). By contrast, SMARCC2 pSer283 and CBX3 pSer95
remain unaffected in TCR- and IL-2-treated cells (supplemen-
tal Table S7) whereas TRIM28 pSer473 and ACLY pSer455 are
induced in both cases.
Metabolic enzymes have emerged as pivotal linkers be-
tween signaling networks and proliferative responses (67–68).
ACLY is a metabolic enzyme that mediates the conversion of
mitochondrial-derived citrate into acetyl-CoA, an essential
metabolite at the intersection of anabolism and catabolism. Its
enzymatic activity is modulated by phosphorylation, and in
addition to the catalytic autophosphorylation site (His760), at
least three site-specific phosphorylations (Thr447, Ser451 and
Ser455) are known to influence the activity of ACLY (58, 69).
ACLY Ser451-containing peptide was repeatedly detected in
our study but never identified as phosphorylated on that
specific residue, suggesting that Ser451 is unlikely to be phos-
phorylated in resting or cytokine-treated Kit225 T cells. Con-
versely, we demonstrated that ACLY Ser455 becomes phos-
phorylated in IL-2-treated T cells, a modification that is known
to increase up to sixfold the catalytic activity of the enzyme.
ACLY Ser455 phosphorylation has also been demonstrated in
TCR-stimulated cytotoxic T lymphocytes (65) and also in IL-
3-treated hematopoietic cells (56). Therefore, distinct mito-
genic signals affecting immune cells may converge on the
phosphorylation on this specific residue of ACLY to elicit a
related cellular response. Notably, among the signaling path-
ways that are activated in response to IL-2, our results indi-
cate that PI3K/AKT pathway is responsible for the phosphor-
ylation of ACLY Ser455 in T cells (Fig. 8).
ACLY has recently emerged as a relevant therapeutic target
in anti-cancer treatments because of the capacity of its prod-
uct acetyl-CoA to promote proliferation in yeast and mamma-
lian cells (70–72). The acetyl-CoA generated through ACLY
activity is the building block for the biosynthesis of fatty acids
FIG. 7. ACLY influences the histone acetylation level of IL-2-treated T cells. A, Acetylation of acid-extracted histones from starved T cells
and T cells grown with IL-2 in the presence or absence of ACLY inhibitor. SAHA deacetylase inhibitor was used as control. B, Chromatin
immunoprecipitation was performed with antibodies against acetylated H3 (AcH3) and AcH4 using starved T cells and T cells grown IL-2 in the
presence or absence of ACLY inhibitor. Purified DNA was analyzed by Q-PCR using primers close to transcription start site of CDC25, CDK1,
E2F2 and CYCA genes. Data are presented as percentage of input chromatin.
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and cholesterol (73) and also serves as substrate for acetyla-
tion reactions that affect a plethora of cellular functions both
in the cytoplasm and nucleus (74–76). In line with this, we
demonstrate here that ACLY inhibition is accompanied by a
reduction of overall histone acetylation levels that could lead
to suppression of IL-2-induced T-cell growth. A similar effect
was observed upon down-regulation of AKT, the kinase in-
volved in the phosphorylation of ACLY Ser455 in Kit225 T-
cells. Interestingly, Lee and colleagues have recently shown
that AKT-dependent phosphorylation of ACLY is sufficient to
sustain high histone acetylation levels in LN229 glioblastoma
cells even when nutrients are limited (71). In line with this, we
observed that inhibition of ACLY abolished IL-2-induced his-
tone acetylation on the promoter of key proliferation-related
genes such as E2F2 and CDK1, which correlated with a
reduction of gene expression and subsequent arrest at the
G1/S transition of the cell cycle (Fig. 7). Nevertheless, it is
unlikely that the function of nuclear ACLY is restricted to
modulating the acetylation of histones; acetylation of addi-
tional proteins such as transcription factors may also be af-
fected by ACLY activity. Furthermore, ACLY is also present in
the cytoplasm of Kit225 T cells where it follows the same
IL-2-dependent regulation of phosphorylation as the nuclear
population. Thus, in addition to its nuclear function, ACLY
probably performs a cytoplasmic function by triggering the
lipogenic pathway in IL-2-treated Kit225 T cells. The anti-
proliferative effects observed upon ACLY inhibition in T cells
may partially be the result of a disrupted lipid metabolism.
Indeed, several studies have shown that inhibition or deple-
tion of the enzyme results in impaired lipid synthesis and
subsequent tumor growth suppression (56–57, 73). Further
investigation will clarify the role of cytoplasmic ACLY in me-
diating IL-2 initiated proproliferative pathways.
Recently, two additional sources of nuclear acetyl-CoA
have been described and both were detected in our large-
scale phosphoproteomics study. Mitochondrial pyruvate de-
hydrogenase complex (PDC) has been shown to translocate
into the nucleus of human lung carcinoma cells, and to gen-
erate acetyl-CoA from pyruvate, which can be used for epi-
genetic regulation (77). According to our data the three inhib-
itory phosphorylations on the E1 alpha subunit of PDC
(Ser232, Ser293, and Ser300) remain unaffected by IL-2 treat-
ment, indicating that although inactive, PDC localizes to the
nucleus of human leukemic Kit225 T lymphocytes. Similarly,
we detected two non-regulated phosphosites of unknown
function corresponding to acetyl-CoA synthetase (ACSS2),
which generates acetyl-CoA using acetate as substrate. Al-
though we cannot come to any conclusion regarding the
activity of ACSS2, our data suggests that this metabolic en-
zyme is present in the nucleus of CD4 T cell, consistent with
other reports (59). Despite the coexistence of several acetyl-
CoA-generating enzymes in the nucleus of Kit225 T cells,
considering the impact of ACLY inhibition in IL-2-triggered
histone acetylation, it is likely that ACLY is the principal
source of nuclear acetyl-CoA in the nucleus of Kit225 T cells.
In summary, we have conducted a quantitative phospho-
proteomic screen that has uncovered the complexity of phos-
phorylation-dependent nuclear IL-2 regulatory networks. A
large set of putative candidates have been identified, which
could be used in future studies. Characterization of the role of
additional players in IL-2-induced T-cell growth should give a
better understanding of the molecular events initiated by the
cytokine that may help design more efficient and less harmful
therapies.
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